Italia markets close in 3 hours 18 minutes

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,4200+0,0500 (+3,65%)
Alla chiusura: 04:00PM EDT
1,4205 +0,00 (+0,04%)
Preborsa: 08:00AM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,3700
Aperto1,3200
Denaro1,3700 x 600
Lettera1,4600 x 600
Min-Max giorno1,3200 - 1,4700
Intervallo di 52 settimane0,5900 - 2,3100
Volume1.018.581
Media Volume1.640.885
Capitalizzazione177,932M
Beta (5 anni mensile)1,24
Rapporto PE (ttm)N/D
EPS (ttm)-0,2400
Prossima data utili13 mag 2024 - 17 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A4,58
  • GlobeNewswire

    Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

    SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023. Details of the company's participation are as follows: Cantor Fitzgerald Global Healthcare Conference 2023Format: Fireside Chat with

  • GlobeNewswire

    Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

    Achieved significant enrollment milestones in three ongoing Phase 2 clinical trialsBroadened patent protection for proprietary (Z)-endoxifenStrengthened management team with appointment of Greg Weaver as Chief Financial OfficerEnded second quarter 2023 with $99.4 million of cash and cash equivalents SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unme

  • GlobeNewswire

    Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

    SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in cancer, today announced that it will provide a business update and report financial results for the second quarter 2023 on Monday, August 14, 2023. Company management will host a conference call to review the results at 9:00 a.m. ET / 6:00 a.m. PT on August 14, 2023. Second Quarter 2023 Conference Cal